Evidence map›Paper›PMID 24367256›Full record

ArticlePLoS pathogens2013

Hypoxia inducible factor signaling modulates susceptibility to mycobacterial infection via a nitric oxide dependent mechanism.

Philip M Elks, Sabrina Brizee, Michiel van der Vaart, Sarah R Walmsley, Fredericus J van Eeden, Stephen A Renshaw, Annemarie H Meijer

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 151 citations in OpenAlex.

  1. mBio · 2026
    Article
  2. Article
  3. Article
  4. Journal of bacteriology · 2025
    Review
  5. Review
  6. Article
  7. Article
  8. ZebrafishLife science alliance · 2024
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Neutrophils inVaccines · 2023
    Review
  17. Review
  18. A Fun-Guide to Innate Immune Responses to Fungal Infections.Journal of fungi (Basel, Switzerland) · 2022
    Review
  19. Article
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Philip M ElksInstitute of Biology, Leiden University, Leiden, The Netherlands.
Sabrina BrizeeInstitute of Biology, Leiden University, Leiden, The Netherlands.
Michiel van der VaartInstitute of Biology, Leiden University, Leiden, The Netherlands.
Sarah R WalmsleyAcademic Unit of Respiratory Medicine, Department of Infection and Immunity, University of Sheffield, Western Bank, Sheffield, United Kingdom.
Fredericus J van EedenMedical Research Council Centre for Developmental and Biomedical Genetics, University of Sheffield, Western Bank, Sheffield, United Kingdom ; Department of Biomedical Science, University of Sheffield, Western Bank, Sheffield, United Kingdom.
Stephen A RenshawAcademic Unit of Respiratory Medicine, Department of Infection and Immunity, University of Sheffield, Western Bank, Sheffield, United Kingdom ; Medical Research Council Centre for Developmental and Biomedical Genetics, University of Sheffield, Western Bank, Sheffield, United Kingdom.
Annemarie H MeijerInstitute of Biology, Leiden University, Leiden, The Netherlands.
Leiden University · NLUniversity of Sheffield · GBMedical Research Council · GB

Funding

Medical Research Council G0701932Medical Research Council G108/595Wellcome Trust 098516
6 · The paper itself

Abstract

Tuberculosis is a current major world-health problem, exacerbated by the causative pathogen, Mycobacterium tuberculosis (Mtb), becoming increasingly resistant to conventional antibiotic treatment. Mtb is able to counteract the bactericidal mechanisms of leukocytes to survive intracellularly and develop a niche permissive for proliferation and dissemination. Understanding of the pathogenesis of mycobacterial infections such as tuberculosis (TB) remains limited, especially for early infection and for reactivation of latent infection. Signaling via hypoxia inducible factor α (HIF-α) transcription factors has previously been implicated in leukocyte activation and host defence. We have previously shown that hypoxic signaling via stabilization of Hif-1α prolongs the functionality of leukocytes in the innate immune response to injury. We sought to manipulate Hif-α signaling in a well-established Mycobacterium marinum (Mm) zebrafish model of TB to investigate effects on the host's ability to combat mycobacterial infection. Stabilization of host Hif-1α, both pharmacologically and genetically, at early stages of Mm infection was able to reduce the bacterial burden of infected larvae. Increasing Hif-1α signaling enhanced levels of reactive nitrogen species (RNS) in neutrophils prior to infection and was able to reduce larval mycobacterial burden. Conversely, decreasing Hif-2α signaling enhanced RNS levels and reduced bacterial burden, demonstrating that Hif-1α and Hif-2α have opposing effects on host susceptibility to mycobacterial infection. The antimicrobial effect of Hif-1α stabilization, and Hif-2α reduction, were demonstrated to be dependent on inducible nitric oxide synthase (iNOS) signaling at early stages of infection. Our findings indicate that induction of leukocyte iNOS by stabilizing Hif-1α, or reducing Hif-2α, aids the host during early stages of Mm infection. Stabilization of Hif-1α therefore represents a potential target for therapeutic intervention against tuberculosis.

Indexed as

Mycobacterium marinumAnimalsAnimals, Genetically ModifiedBasic Helix-Loop-Helix ProteinsCells, CulturedDisease Models, AnimalEndothelial PAS Domain-Containing Protein 1Genetic Predisposition to DiseaseHypoxia-Inducible Factor 1, alpha SubunitMycobacterium Infections, NontuberculousNeutrophilsNitric OxideNitric Oxide Synthase Type IINitrosationSignal TransductionZebrafishBasic Helix-Loop-Helix ProteinsEndothelial PAS Domain-Containing Protein 1Hypoxia-Inducible Factor 1, alpha SubunitNitric OxideNitric Oxide Synthase Type II

Identifiers

PMID24367256
PMCPMC3868520
OpenAlexW2141166469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.